PremiumRatingsPrecigen’s Promising Outlook: Buy Rating Backed by Strategic Initiatives and PRGN-2012’s Potential FDA Approval Strategic Developments and Promising Pipeline Position Precigen for Growth: A Buy Rating by Jason Butler Precigen Reports Progress and Financial Results for 2024 PremiumThe FlyPrecigen price target raised to $6 from $4 at H.C. Wainwright Biotech Alert: Searches spiking for these stocks today Precigen Secures $79M Financing for 2025 Launch PremiumCompany AnnouncementsPrecigen Reports Q3 2024 Financial Results Precigen reports Q3 EPS (9c), consensus (8c) PGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings? 
